8-K: Contineum's PIPE-791 Phase 1b PET Trial Shows Positive Data

Contineum Therapeutics announced positive topline data from its PIPE-791 Phase 1b PET trial, demonstrating high LPA1 brain receptor occupancy and a consistent safety profile.

Summary

• PIPE-791 achieved high LPA1 brain receptor occupancy (RO) in both healthy volunteers and progressive multiple sclerosis (PrMS) patients.
• A clear pharmacokinetic (PK) correlation was confirmed between drug exposure and receptor engagement.
• The drug demonstrated a safety and tolerability profile consistent with previous clinical studies.
• Plasma EC50 values of 37 ng/mL at 24 hours and 12 ng/mL at 168 hours post-dose indicated sustained target engagement in healthy volunteers.
• The company believes its planned doses for future Phase 2 proof-of-concept clinical trials in idiopathic pulmonary fibrosis (IPF) and PrMS will exceed 90% target coverage at trough with once-daily dosing.
• The Phase 1b, open-label, single-center trial included 12 healthy volunteers and four PrMS patients.

Sentiment

Score: 8

Explanation: The positive topline data from the Phase 1b PET trial for PIPE-791, demonstrating high receptor occupancy and a consistent safety profile, provides strong validation for advancing the drug into Phase 2 trials. This significantly de-risks the early development stage and supports the company's strategic direction, despite the inherent risks of clinical development.

Positives

• High LPA1 brain receptor occupancy achieved in healthy volunteers and progressive multiple sclerosis (PrMS) patients.
• A clear pharmacokinetic (PK) correlation between drug exposure and receptor engagement was confirmed.
• Safety and tolerability profile consistent with previous clinical studies.
• Sustained target engagement demonstrated by plasma EC50 values of 37 ng/mL at 24 hours and 12 ng/mL at 168 hours post-dose.
• Planned doses for future Phase 2 clinical trials are expected to exceed 90% target coverage at trough with once-daily dosing.
• Brain receptor occupancy is considered an appropriate surrogate for predicting RO in the lungs, despite technical challenges in direct lung measurement.

Negatives

• Direct measurement of LPA1 receptor occupancy in the lungs of healthy volunteers was not feasible due to low receptor expression and technical challenges with lung PET imaging.

Risks

• Heavy dependence on the success of PIPE-791 and PIPE-307, both in early clinical development, which may not progress through clinical development or receive regulatory approval.
• Results of earlier preclinical studies and clinical trials may not be predictive of future results, and unexpected adverse side effects or inadequate efficacy could limit development.
• The timing and outcome of research, development, and regulatory review are uncertain.
• Regulatory authorities (e.g., U.S. FDA) may disagree with the design or implementation of proposed clinical trials.
• Clinical trials and preclinical studies may not proceed at the time or in the manner expected, or at all.
• Programs and prospects could be negatively impacted by developments relating to competitors.
• Reliance on third parties to successfully conduct clinical trials and, for PIPE-307, reliance on Janssen Pharmaceutica NV for development decisions.
• Significant and increasing operating expenses are expected for the foreseeable future.
• The license agreement with Janssen Pharmaceutica NV may not result in the successful development of PIPE-307.
• Inability to obtain, maintain, and enforce intellectual property protection for technology and drug candidates.
• Unstable market and economic conditions and military conflict may adversely affect the company's business and financial condition.

Future Outlook

The company believes its planned doses for future Phase 2 proof-of-concept clinical trials in idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS) will exceed 90% target coverage at trough with once-daily dosing, based on the positive Phase 1b PET trial data.

Management Comments

• "We are pleased by these results, which confirm that PIPE-791 achieves high, sustained brain RO." Timothy Watkins, M.D., M.Sc., Chief Medical Officer and Head of Development, Contineum Therapeutics.
• "These trial data highlight the unique pharmacological properties of PIPE-791, enabling the potential for once-daily dosing for sustained target coverage." Timothy Watkins.
• "We believe showing target engagement in humans is an important, additional step that validates our compelling preclinical data and provides a solid foundation for advancing PIPE-791 into Phase 2 trials." Timothy Watkins.
• "Based on the distribution pattern of PIPE-791, we believe the brain is an appropriate surrogate for predicting RO in the lungs." Daniel Lorrain, Ph.D., Chief Scientific Officer, Contineum Therapeutics.
• "We are confident in the planned doses for our future Phase 2 proof-of-concept clinical trials based upon brain RO and our completed preclinical work." Daniel Lorrain.

Industry Context

The positive Phase 1b PET trial data for PIPE-791 positions Contineum Therapeutics favorably in the competitive landscape for neuroscience, inflammation, and immunology (NI&I) indications, particularly for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS). Demonstrating high receptor occupancy and a favorable safety profile in early-stage trials is crucial for advancing novel therapies in these areas, where significant unmet medical needs persist. Success in these early stages can attract further investment and partnerships, potentially accelerating development compared to competitors facing similar challenges in drug discovery and clinical validation.

Stakeholder Impact

• Shareholders: Positive trial results could increase investor confidence and potentially lead to stock price appreciation.
• Patients (IPF & PrMS): Offers hope for a new, potentially effective once-daily treatment option for conditions with significant unmet needs.
• Employees: Validates internal research and development efforts, potentially boosting morale and attracting talent.
• Regulatory Authorities: Provides data supporting the progression of a novel drug candidate through the regulatory pathway.

Next Steps

• Advancing PIPE-791 into Phase 2 proof-of-concept clinical trials for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS).

Key Dates

Recommendation

The positive topline data from the Phase 1b PET trial for PIPE-791, demonstrating high LPA1 brain receptor occupancy and a favorable safety profile, significantly de-risks this key pipeline asset. The confirmation of target engagement and the planned once-daily dosing for Phase 2 trials in IPF and PrMS provide a strong foundation for future development. While early-stage, these results validate the company's approach and enhance the long-term potential of PIPE-791, making it an attractive investment for growth-oriented portfolios.

Keywords

Contineum Therapeutics, PIPE-791, LPA1 receptor antagonist, Phase 1b trial, PET trial, progressive multiple sclerosis, idiopathic pulmonary fibrosis, biopharmaceutical, clinical-stage, neuroscience, inflammation, immunology, receptor occupancy, pharmacokinetics